Business Context and Reporting Period
This Form 8-K reports on events occurring on September 22, 2020, filed by Alpha Healthcare Acquisition Corp. (AHAC), a Special Purpose Acquisition Company (SPAC). The filing details the consummation of the Company's Initial Public Offering (IPO) and a concurrent Private Placement. Note: The input metadata references "Humacyte, Inc.", but the filing text explicitly identifies the registrant as Alpha Healthcare Acquisition Corp.
Key Financial Metrics
- IPO Gross Proceeds: $100,000,000 from the sale of 10,000,000 Units at $10.00 per Unit.
- Private Placement Proceeds: $3,550,000 from the sale of 355,000 Units to the Sponsor and underwriters.
- Total Capital Raised: $103,550,000.
- Trust Account Funding: $100,000,000 deposited into a U.S.-based trust account (comprising $98,000,000 from IPO proceeds and $2,000,000 from Private Placement proceeds).
- Deferred Underwriting Fees: $3,500,000 included within the IPO proceeds held in trust.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 1,500,000 additional Units.
- Warrant Exercise Price: $11.50 per share.
Material Changes
The primary material change is the transition from a pre-IPO entity to a publicly traded company on The Nasdaq Stock Market LLC. The Company now has outstanding securities including Class A Common Stock (AHAC), Units (AHACU), and Redeemable Warrants (AHACW). An audited balance sheet as of September 22, 2020, reflecting these proceeds, has been issued.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, risk factors, or management commentary beyond the mechanics of the capital raise. The Company is designated as an emerging growth company. The primary contingency noted is the 45-day over-allotment option held by underwriters to cover potential excess demand.
Investor Verification Checklist
- Verify the identity of the registrant (Alpha Healthcare Acquisition Corp.) versus the metadata label (Humacyte, Inc.).
- Confirm the exact amount of cash held in the trust account ($100,000,000) and the status of deferred underwriting fees.
- Review the terms of the over-allotment option (1,500,000 Units) and its expiration timeline.
- Examine the audited balance sheet provided as Exhibit 99.1 for detailed asset and liability breakdowns.
- Confirm the trading symbols (AHAC, AHACU, AHACW) on Nasdaq.